Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Endo Sues Mylan to Halt Sale of Generic Frova Migraine Drug

Endo Pharmaceuticals Holdings Inc. sued to stop Mylan Inc. from marketing a generic copy of Frova before three patents on the migraine drug expire.

Mylan, based in Canonsburg, Pennsylvania, is seeking approval to make and sell a version of the drug’s 2.5 milligram tablets, Endo said in a complaint filed today in federal court in Wilmington, Delaware.

Endo, based in Chadds Ford, Pennsylvania, asked a judge to bar Mylan from infringing the patents. Frova, used to treat acute migraines in adults, was Endo’s fifth-biggest seller last year, according to data compiled by Bloomberg.

Endo, which markets Frova in the U.S., received notice from Mylan of an abbreviated new drug application last month, according to a filing with the U.S. Securities and Exchange Commission. The notice refers to five U.S. patents covering Frova and expiring between 2013 and 2015.

Nina Devlin, a spokeswoman for Mylan, didn’t immediately return a phone call seeking comment on the suit.

The case is Endo Pharmaceuticals Inc. v. Mylan Pharmaceuticals Inc., U.S. District Court, District of Delaware (Wilmington).

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.